United States · Biotechnology startup
United States · SeLux Diagnostics
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
Funding reportedLast round: Series D
What company datasets say SeLux Diagnostics raised
Funding, as reported
Reported in all$220Min dollars
Rounds10
Last roundSeries D
Last round dateApr 2024
Investors listed7
Founders and team
From the SEC filings it signed: 7 on the team.
- Adam Parker SteelExecutive Officeri
- Aleksandar E. VacicExecutive Officeri
- Eric E. SternExecutive Officer, Directori
- Ingo Parker ChakravartyMr. Chakravarty was elected Director upon the Date of First Sale.i
- John Parker WilsonExecutive Officeri
- Michele Parker HealyExecutive Officeri
- Steven E. LufkinExecutive Officer, Directori
On the board, as filediErich Parker SchellerJames Parker CassidyJamie Parker CondieOrhan Parker Gazelle
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put SeLux Diagnostics in front of investors. Or tell us what we have wrong.